SEC Ruling Could Allow Greater Transparency On Drug Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead and Vertex appealed shareholder requests to disclose the processes behind pricing decisions for Sovaldi, Harvoni and Kalydeco, but SEC rules it does not constitute micromanagement of the companies.